Cargando…
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Chimeric antigen receptor T (CAR T) cell therapy has demonstrated efficacy in the treatment of haematologic malignancies. However, the accompanying adverse events, the most common of which is cytokine release syndrome (CRS), substantially limit its wide application. Due to its unique physiological c...
Autores principales: | Wei, Jianshu, Liu, Yang, Wang, Chunmeng, Zhang, Yajing, Tong, Chuan, Dai, Guanghai, Wang, Wei, Rasko, John E. J., Melenhorst, J. Joseph, Qian, Wenbin, Liang, Aibin, Han, Weidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388484/ https://www.ncbi.nlm.nih.gov/pubmed/32728035 http://dx.doi.org/10.1038/s41392-020-00256-x |
Ejemplares similares
-
Characteristics of premanufacture CD8(+) T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma
por: Wang, Yao, et al.
Publicado: (2023) -
Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies
por: Yan, Xin, et al.
Publicado: (2022) -
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2018) -
CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023) -
Current advances in Hodgkin’s lymphoma
por: Vadakara, Joseph, et al.
Publicado: (2019)